Background
Human α-like globins are encoded by three homologous genes (5′-ζ-α2-α1-3′) arranged in order of their developmental expression [
1]. Embryonic α-like ζ globin is produced during the first gestational trimester in primitive erythroblasts that originate in blood islands of the yolk sac, while fetal/adult α globin is induced at the end of this interval and continues to express in definitive erythroblasts that are initially produced in the liver and, subsequently, in the bone marrow [
1,
2]. Unlike α globin--which is required for normal growth and development both in the uterus and after birth--ζ globin appears to be largely dispensable to mammalian reproduction. Embryonic ζ globin is not required for viability in mice [
3], and naturally occurring deletions and duplications in its encoding gene are not associated with any defined phenotype in man [
2,
4,
5]. As a consequence of this apparent biological irrelevance, then, there has been little incentive to detail the processes that control ζ-globin expression in either primitive or definitive erythropoiesis.
Investigations of the molecular and cellular programs that regulate ζ globin, though, are recently justified by its demonstrated potential as a novel therapeutic for both α thalassemia and sickle-cell disease [
6,
7]. When compelled to express in definitive erythroid cells, embryonic ζ globin assembles with adult β globin into heterotetrameric Hb ζ
2β
2 (Hb Portland-2), which exhibits O
2-binding and allosteric properties that differ modestly from those of Hb α
2β
2 (Hb A, the principal adult hemoglobin), but that remain fully compatible with normal adult physiology [
8,
9]. The significance of this approach for treating α-globin deficiency states (α thalassemia) is illustrated by evidence that transgenic human ζ globin fully reverts the pathological phenotype of mice containing heterozygous knockout of their endogenous α-globin genes and, remarkably, restores full viability to animals with homozygous, embryonic-lethal inactivation of these same genes [
6]. The developmental stage-discordant expression of ζ globin holds additional therapeutic promise for sickle-cell disease, as its low-level expression effectively mitigates the abnormal phenotype of mouse models of this disorder [
7,
10]. Importantly, the α → ζ exchange that converts pathological Hb α
2β
S2 (Hb S) to non-pathological Hb ζ
2β
S2 does not exclude the mutant β
S subunit, raising the possibility that this novel strategy can be coordinated with contemporary therapies that promote β
S → γ exchange. These two developing applications for ζ globin--effected through either gene-reactivation or gene-supplementation strategies--now recommend careful description of the events that contribute to its regulation in definitive erythroid cells.
Post-transcriptional regulatory processes are critical to the normal accumulation of adult α- and β-globins in definitive erythrocytes, ensuring that the cognate mRNAs are maintained at high levels in transcriptionally silent--but translationally active--progenitor cells. The fundamental bases for the prolonged half-life (t
1/2) values for both α- and β-globin mRNAs have now been established in detail, including the identification of specific
trans-acting effector proteins and the
cis-acting regulatory elements that they target [
11‐
16]. Similar analyses of embryonic ζ-globin transcripts that are expressed either physiologically or following therapeutic derepression in definitive erythropoiesis indicate that the mRNAs are subject to post-transcriptional processes that are constitutive to these cells [
17,
18]. While ζ-globin mRNA is observed at low levels in normal adult erythroid progenitors [
19‐
21], it can accumulate to significantly higher levels in cells where its encoding gene is transcriptionally dysregulated [
22‐
24], implicating the presence of active post-transcriptional processes that are capable of acting upon developmental stage-discordant ζ-globin mRNA. Transgenic human ζ globin can also be produced in abundance in adult mice (at levels that support viability in α-globin nullizygotes) [
6], validating the assertion that--as a practical matter--the half-life of its encoding mRNA is sufficiently long to ensure that biologically relevant levels of ζ globin are translated [
6‐
9]. These principles are confirmed in individuals with Southeast Asian-type α thalassemia [
25], congenital dyserythropoietic anemia [
26], and juvenile chronic myelocytic leukemia [
24], who express measurable quantities of both ζ-globin mRNA and ζ-globin protein. Collectively, these observations endorse the likelihood that post-transcriptional programs in adult erythropoiesis are fully permissive for the expression of ζ-globin mRNA.
The present work describes structures within the ζ-globin 3′UTR that are critical to its post-transcriptional regulation, illustrates their effects on the half-life value of the full-length ζ-globin mRNA in intact cells, and identifies a trans-acting factor that is likely to mediate this process. These results provide a foundation for understanding the impact of post-transcriptional activities to the developmental stage-discordant expression of ζ globin in adult erythropoiesis, as a promising therapeutic for both α thalassemia and sickle-cell disease.
Discussion
Recent reports that ζ globin acts as a physiological surrogate for deficient α globin [
8,
9] and efficiently inhibits the pathological polymerization of deoxyHb S [
7,
10] have engendered substantial interest in developing this embryonic globin as a unique and highly effective therapeutic for α thalassemia and sickle-cell disease, respectively. The premise that developmentally silenced globin genes can be derepressed in definitive erythroid cells is consistent with observations that ζ globin is expressed at high levels in several congenital and acquired conditions in humans [
24‐
26] and can be reactivated by mutations that target transcriptional regulatory elements in animals [
22‐
24]. Developmental stage-discordant embryonic globins can also be expressed from transgenes that have been modified to contain adult-stage promoters and enhancers [
6,
17,
22]. While the specific mechanisms that underlie transcriptional repression of embryonic globin genes in definitive erythropoiesis remain a matter of active investigation, it is clear that this process can be reversed in adult erythroid progenitors.
An equally important determinant of ζ-globin expression--its
post-transcriptional regulation--has been studied less extensively in both primitive and definitive erythropoiesis. Processes that impart high stability to globin mRNAs are particularly important in adult erythroblasts, permitting these transcripts to accumulate to high levels and to translate globin protein for 3–5 days following nuclear condensation and extrusion from orthochromatophilic erythroblasts [
1]. As might be predicted, mutations that impair the high stabilities of globin mRNAs in transcriptionally silent cells will disproportionately impact the levels of their encoded proteins. For example, a naturally occurring antitermination mutation that shortens the t
1/2 of α-globin mRNA to ~25% of its normal value (α
Constant Spring) coordinately reduces expression of the cognate globin monomer to ~2% of the wild-type value [
49,
50]. Without some knowledge of the half-life of ζ-globin mRNA, on the mechanism through which it is stabilized in definitive erythroid cells, it is difficult to predict whether transcriptional derepression of the ζ-globin gene transcription will necessarily achieve the desired therapeutic effect.
We previously observed a modest difference in the stabilities of human α-and ζ-globin mRNAs that were compelled to express in definitive mouse erythroid cells [
18]. This effect, which mapped to single-nt differences in homologous pyrimidine-rich elements (PREs) positioned within the two 3′UTRs, was attributed to a 6-fold reduction in the affinity of the ζ-PRE for αCP (hnRNP E), a cytoplasmic mRNA-binding protein that effects the high stability of α-globin mRNA [
12,
18]. Importantly, ζ-globin mRNA was not fully stabilized by exchange of the ζ-PRE for the corresponding α-globin determinant, suggesting the activities of other, structurally dissimilar mRNA-stabilizing elements [
18]. The present study validates this hypothesis, as it identifies a unique site-specific region of 3′UTR that is essential for the normal cytoplasmic accumulation of ζ-globin (Figures
1 and
2). Subsequent half-life analyses, conducted
in vivo in intact cultured cells, directly demonstrate the importance of the ZMRE (and, specifically, its 4-nt cytosine-rich core) to the cytoplasmic stability of ζ-globin mRNA (Figures
3 and
4).
Our several measures suggest a t
1/2 value of 11–15 hr for ζ-globin mRNA in HeLa cells (Figures
3 and
4), which is surprisingly close to a t
1/2 value of ~11 hr for α-globin mRNA obtained in MEL cells using a similar strategy [
50]. The similar stabilities of α- and ζ-globin mRNAs in these cultured cells--which do not express other globin mRNAs in significant quantities--contrasts sharply with their discordant stabilities in primary mouse cells that co-express high levels of endogenous α-globin mRNA [
18]. The cell context-dependent difference in the relative stabilities of the α- and ζ-globin mRNAs suggests that they may be co-regulated through a shared post-transcriptional mechanism. We previously described a similar relationship among developmentally related β-like globin mRNAs, where the stabilities of transgenic embryonic ϵ- and fetal γ-globin mRNAs are reduced in the presence of adult β-globin mRNA [
35,
36]. A similar relationship between the ζ- and α-globin mRNAs would account for the significant reduction in the half-life of ζ-globin mRNA when co-expressed with α-globin mRNA of either human or mouse origin. The implications of this mechanism vis-à-vis α thalassemia are substantial, as expression of ζ-globin mRNA from a therapeutic transgene would self-correct to higher or lower levels in patients with more or less severe deficits in α-chain production, respectively.
Our results also indicate that the stability of ζ-globin mRNA in definitive erythropoiesis reflects a balance between at least two separate post-transcriptional programs. The ZMRE that we identify is distinct from the previously identified ζ-PRE in both its position within the 3′UTR as well as the specific
trans-acting factors that it binds (Figure
7). Specifically, the ZMRE binds AUF1, a
trans-acting mRNA-binding protein implicated in both the stabilization and destabilization of heterologous mRNAs in erythroid and non-erythroid cells [
16,
47,
48]. This interaction may account for the observation that ZMRE-related activities are readily observed in non-erythroid HeLa cells (Figures
3 and
4), while αCP-mediated programs that stabilize α-globin mRNA are largely restricted to erythroid cells [
11]. Importantly, AUF1 stabilizes β-globin mRNA through interaction with a 3′UTR determinant [
16], suggesting potential mechanistic overlap between programs that direct the stabilities of α-like and β-like mRNAs or, conceivably, the stabilities of embryonic and adult globin mRNAs. Both possibilities would be consistent with dynamic post-transcriptional competition between embryonic and adult globin transcripts [
36] and would predict that the efficiency of ζ-globin derepression in α thalassemia would be proportional to the severity of the α-chain deficit.
One remarkable property of the ZMRE is its apparent non-autonomous function (Figure
5), suggesting ‘allosteric’ effects of surrounding structures on the activity of this determinant (Figure
6). While our studies do not investigate the positions of these function-modifying structures, we think it unlikely that they reside in coding region mRNA which is constantly remodeled by actively translating ribosomes. It seems reasonable to speculate that ZMRE activity is instead enforced by interactions with other regions of 3′UTR (or factors that they bind), or by structural interface with the ζ-globin 5′UTR. The latter process might resemble the ‘closed-loop’ model for mRNA translation that invokes structural interactions between the 5′UTR, 3′UTR, and polyadenylate tail [
51‐
55]. The experimentally determined structure surrounding the ZMRE is fully consistent with this possibility (Figure
6), predicting its positioning on an internal loop and/or within a hydrophobic nucleotide stack, where effector
trans-acting factors might bind and subsequently alter the regional structure to reveal (or conceal) co-determinants of mRNA stability.
Methods
Gene construction
Parental pTRE2Aζ was derived from pTRE2 (Clontech) by inserting the full-length human ζ-globin gene (including ~100 nt of contiguous 5′- and 3′-flanking regions) into the polylinker
Sac II-
Bam HI site. A ~1.0 kb
Nco I-
Sap I vector fragment was subsequently deleted to eliminate a default polyadenylation signal that competes with the native ζ-globin poly(A) signal. 3′UTR-derivative ζ-globin genes were constructed from pTRE2Aζ by exchanging the exon III
Bst EII-polylinker
Bam HI fragment with 330-bp synthetic DNAs (Genscript), each encompassing a mutated ζ-globin 3′UTR. The construction of a corresponding full-length β-globin gene (pTRE2Aβ) is described elsewhere [
15]. Genes encoding chimeric βζ-globin mRNAs were generated from pTRE2Aβ by exchanging the parental
Eco RI-
Eco NI DNA fragment (encompassing β-globin exon III and contiguous 3′-flanking region) for a corresponding synthetic DNA containing the desired wild-type or derivative ζ-globin 3′UTR. All recombinant DNAs were validated by automated sequencing.
Cell culture
HeLatTA cells expressing the tetracycline transactivator fusion protein (tTA; Clontech) were maintained in DMEM supplemented with 10% FBS and antibiotics, at 37°C in a humidified 5% CO2 environment. Wild-type and 3′UTR-derivative pTRE2Aζ vectors used for stable transfections were modified by inserting a 1.5-kb DNA fragment encoding hygromycin (hyg) resistance into a unique vector Xho I site. Approximately 6×105 cells were transfected with 5.0 μg of DNA using Superfect reagent under conditions recommended by the manufacturer (Qiagen), and selected with 400 μg/mL hyg. Hyg-resistant clones were tested by RT-qPCR for levels of ζ-globin mRNA and control endogenous β-actin mRNA. Tetracycline (tet) response was assessed by quantifying the level of ζ-globin mRNA, relative to the level of tet-indifferent β-actin mRNA, following a 48-hr incubation in tet-supplemented media (2 μg/mL).
mRNA decay analyses
Two-point decay analyses were conducted on 5×105 preplated HeLatTA cells maintained in tet-supplemented medium (0.5 μg/mL). Cells were transfected with 5.0 μg DNA comprising equal quantities of wild-type (or 3′UTR-derivative) TRE2Aζ and control pTRE2Aβ using Superfect reagent, and replated as two aliquots for overnight growth in tet-supplemented medium (0.03 μg/mL). PBS-washed aliquots were then incubated for five hr in tet-free medium; one aliquot was sacrificed immediately (t = 0) and a second aliquot after an additional 16-hr incubation in tet-supplemented medium (2.0 μg/mL). Conventional half-life analyses were conducted on 2×106 HeLatTA cells maintained in tet-supplemented medium (0.5 μg/mL), transfected with 10 μg DNA using Superfect reagent, and then replated in aliquots in tet-supplemented medium (0.03 μg/mL) for overnight growth. PBS-washed aliquots were then incubated in tet-free medium for five hr, supplemented with tet (2.0 μg/mL) and sacrificed at defined intervals. For both transient and stable analyses, cells were sacrificed by immersion in Trizol, and RNA prepared as recommended by the manufacturer (Invitrogen). Purified RNA was resuspended at 10 μg/mL in H2O, and stored at −80°C.
RT-qPCR
Purified RNA (50 ng) was assayed using Taqman One-Step reagents on a model 7500 real-time PCR system, using protocols recommended by the manufacturer (Applied Biosystems; AB). Analyses were conducted using assays for human ζ globin (AB catalogue HS00923579_m1), β globin (HS00747223_g1), and β actin (HS99999903_m1), and quantified by ΔΔCt methodology that we describe elsewhere [
34]. Relative decay values were calculated as the quantity of each ζ-globin mRNA remaining after a 16-hr transcriptional chase interval, relative to transiently co-expressed β-globin mRNA; the relative decay of ζWT mRNA was arbitrarily assigned unit value. p values--where indicated--were calculated using standard Student t-test methods.
Affinity enrichment
Custom 5′-terminal biotinylated single-strand (ss) DNAs corresponding to 3′UTRs from ζWT (5′TGGAGGTTCCCCAGCCCCACTTACCGCGTAAT3′), ζ57 (5′TGGAG GTTAGTGCACACCACTTACCGCGTAAT3′), and ζ65 (5′TGGAGGTTCCCCAGCCAGTGCACACGCGTAAT3′) mRNAs were commercially sourced (IDT). Approximately 1 μg of each ssDNA was incubated overnight at 4°C in 500 μL cytoplasmic extract supplemented with 50 μL ImmunoPure Avidin Agarose beads (Pierce). The pelleted beads were washed 2× with PBS + Triton-×100 (0.05%) and 2× with PBS + Triton-×100 (1.0%), resuspended in 10 μL loading buffer, and resolved on a precast 4-12% gradient SDS-polyacrylamide gel (Invitrogen). Cytoplasmic extracts were prepared from ~1×107 cells lysed in buffer (1 mM Hepes pH 7.9, 0.15 mM MgCl2, 1 mM KCl) and clarified by centrifugation at 13000xg for five minutes at 4°C; extract was stored in aliquots at −80°C.
Proteomics
Analyses were conducted by the University of Pennsylvania Proteomics Core Facility. Tryptic digests were studied by nanoLC/MS/MS using Thermo LTQ and Eksigebt nano LC-2 Da instruments, and data analyzed from the Uniprot_Sprot database using Sequest and Scaffold software packages. Statistical p-value cutoffs of 95.0% and 99.0% were applied for peptides and proteins, respectively.
Western transfer
Antibodies were used at the following dilutions: AUF1 (kind gift of G Dreyfuss; 1:2000), replication protein A (Santa Cruz SC-81373; 1:300), and hnRNP-H (Santa Cruz SC-10042; 1:500). Cytoplasmic extracts were resolved on precast 4-12% SDS-polyacrylamide gels, then transferred to nitrocellulose using an XCell II Module per manufacturer recommendations (Invitrogen). Membranes were blocked for 30 minutes at room temperature (RT) with Superblock T20 (Thermo Scientific), then supplemented with primary antibody for 60 min and with secondary HRP-conjugated antibody for an additional 30 minutes. Immunoblots were washed thrice for five minutes at RT with PBS + Tween-20 (0.1%), and analyzed by ECL chemiluminescence (GE Healthcare).
mRNA secondary structure
A DNA template for
in vitro transcription of the ζ
WT 3′UTR, containing an 18-nt polyadenylate tail, was directionally inserted into the
Xho I-
Bgl II polylinker site of pSP72. The
Bgl II-linearized plasmid was transcribed
in vitro as previously described [
41], and the purified RNA then 5′-end labeled with [γ-
32P]ATP using a Kinase Max kit (Ambion). The [
32P]-labeled RNA was digested with RNase A (100, 10, 1.0, and 0.1 ng/mL), RNase T1 (100, 10, 1.0, and 0.1 mU/μL), or RNase V1 (10, 1.0, 0.1, and 0.01 mU/μL) as directed by the supplier (Ambion). RNases A and T1 exhibit cleavage specificities for pyrimidine and guanosine bases in single-stranded regions of RNA, respectively, while RNase V1 cleaves 3′ to nucleotides within double-stranded regions of RNA. Reaction products were resolved on a 33 cm × 40 cm 6%:8 M acrylamide:urea gel, in parallel with a migration-control ‘ladder’ generated by alkaline hydrolysis of [
32P]-labeled transcripts [
41].
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Participated in research design: ZH, DS, SvZ, JER. Conducted experiments: ZH, DS, SvZ. Performed data analysis: ZH, JER. Wrote or contributed to the writing of the manuscript: JER. All authors read and approved the final manuscript.